During the preclinical, early clinical, late-stage clinijury is extremely low. During the pharmaceutical discal, and postmarketing phases of the pharmaceutical discovery and development process, one important as-covery, development, and marketing processes, drugpect of drug safety assessment involves monitoring for associated hepatotoxicity can be encountered at any of possible drug-induced hepatic injury. Hepatic injuries four stages.
asymptomatic. A fairly large number of drugs fall results. In humans, the incidence of fatty liver disease noted at autopsy for accident victims ranges from 40 within this category. These are not typically discontinued for this phenomenon alone. For example, the to 80% (Hodgson et al., 1989) suggesting a high incidence from unknown causes in the general adult popu-U.S. Physicians' Desk Reference indicates that liver enzyme elevations may be found in up to 15% of patients lation. Necrotic cell death is accompanied by a disruption of cell membrane integrity and the loss of livertaking nonsteroidal anti-inflammatory drugs (NSAIDs). One NSAID in particular, sulindac, actually accounts specific enzymes which forms the basis of the serum chemistry analyses used systematically for its detecfor most of the risk (Fry and Seeff, 1995; Garcia Rodriguez et al., 1994) . Another example is the 12% inci-tion. Clinical manifestations of hepatic necrosis and degeneration range from jaundice to fulminant hepatic dence of asymptomatic hepatic enzyme abnormalities reported in ketoconazole recipients (Mosca et al., 1985) . failure. Cholestatic injury occurs when there is a disruption or impairment of bile flow. Canalicular choleThe disease under treatment may also affect the liver adversely leading to elevated hepatic enzymes. Most of stasis can be caused by several mechanisms including leaky paracellular junctions, a diminished contractility these reactions are host-dependent, idiosyncratic responses which are not easily predicted in preclinical of canaliculus, diminished transcytosis, impaired transporters, and toxin concentration in the paracanitesting or observed in early clinical trials because of the small number of subjects. cular area (Moslen, 1996) . Toxins or their metabolites can also damage the intrahepatic bile ducts. ChlorThe final stage involves similar findings in a large postmarketing population. These cases involve very-promazine, oral contraceptives, and androgens used to increase muscle mass can produce a cholestatic relow-frequency, idiosyncratic (type B) events that are not detectable in controlled clinical populations of 500-sponse. Hepatobiliary lesions lead to elevated serum levels of bile constituents or enzymes localized in the 1000, for example, due to mathematical probability. These result from a novel aspect of the patient, not the hepatobiliary tree such as Alk P or gamma glutamyltranspeptidase (GGT; EC 2.3.2.2). In humans, most hedrug, and are more uncertain in etiology because they are typically reported in an uncontrolled nonclinical patic drug reactions appear within 3 months of starting therapy (Davis, 1989) . setting. Thus, drug-induced hepatic injury ranges from frequent, dose-related effects in multiple species to rare but profound hepatic effects only detectable in suscepti-
BIOCHEMICAL TESTS USED FOR THE DETECTION ble individuals at therapeutic doses. Serum transami-

OF HEPATIC INJURY
nase activities are the single diagnostic indicator for all of these effects and are the subject of this review.
Categories of Laboratory Tests
Three categories of noninvasive laboratory tests are
HISTOLOGICAL TYPES OF TOXIC HEPATIC INJURY
used to identify the type and extent of drug hepatotoxicity based on the presence or absence of specific markIn general, the type and degree of acute toxic liver injury following drug administration depend upon the ers in the blood of exposed individuals. The first category of clinical assays is that used to assess hepatoceldose and duration of exposure. In addition, many chemicals preferentially affect certain cell populations but lular damage leading to liver cell necrosis. Evidence of this type of injury is based on the detection the hepatic not others in the same host. Major histologic lesions of the liver due to chemical toxicity include fatty change, transaminases, alanine aminotransferase (ALT), and aspartate aminotransferase (AST). These are not norhepatocellular death, and hepatobiliary lesions. Granulomatous and mixed histological changes may also be mal components of blood and serve no known function outside the organ of origin. A third specific marker of seen or venoclusive effects, especially with some antineoplastic drugs (McDonald hepatocellular damage, serum F protein, has been recently described (Foster et al., 1989) , although it is not and Tirumali, 1984). Steatosis or fatty change refers to an increase in hepatic lipid content greater than 5% yet as widely used as the transaminases. Based on liver biopsy specimens, chronic ALT elevations in asympby weight (Moslen, 1996) . Lipid accumulates as intracytoplasmic vacuoles in either a zonal or diffuse pat-tomatic patients have also been associated with fatty liver (Hulteranz et al., 1986) . In fact, nonalcoholic tern. Microvesicular and macrovesicular steatoses, differing in the lipid vacuole size and the mechanism for steatosis has been cited as a very common cause of chronic ALT elevations in the general population their formation, are distinguishing characteristics of specific toxicants. Macrovesicular steatosis is charac- (Craxi and Almasio, 1996) . Thus, transaminase elevations are indicative of hepatocellular death and fatty terized by a single large fat droplet which displaces the nucleus to the cell periphery, but in microvesicular degeneration in particular, but can also be used in conjunction with other serum enzymes for distinguishing steatosis there are a number of small lipid droplets that do not displace the nucleus (Stricker, 1992a) . non-hepatocellular injury as described below.
The second group of tests includes markers for hepaSteatosis is reversible unless it is persistent enough to cause secondary changes or so severe that cell death tobiliary (chlolestatic) effects. This type of injury in-cludes biliary obstruction or hepatic infiltrative pro-dogs and rats (Waner and Nyska, 1991) , cefazolin cesses resulting in the retention of bile acids in liver which significantly depresses ALT and AST activities and leading to drug-induced jaundice if severe. Serum in rat liver (Dhrami et al., 1979) , and isoniazid which markers include Alk P from the cell canalicular mem-significantly inhibits hepatic and serum AST in robrane, 5 nucleotidase (5NT), and GGT. Neither Alk P dents (Yamada et al., 1984a,b) . In addition to inhibinor GGT, which is also inducible by alcohol and certain tory effects by antivitamin B6 compounds, transamidrugs (see below), is liver-specific. However, marked nase levels are effected by other nutritional events. serum Alk P elevations, especially when accompanied For example, healthy human volunteers ingesting a by 5NT or GGT elevations, suggest mechanical bile choline-deficient diet for 4 weeks showed significantly duct obstruction, primary sclerosing cholangitis, pri-elevated levels of ALT compared their cohorts (Zeisel mary biliary cirrhosis, or drug-induced hepatitis et al., 1991) . A discussion of the characteristics of each (Herlong, 1994) . Thus, serum enzyme profiles as op-of these important enzymes follows. posed to individual enzyme changes are used for diagnostic purposes, especially for monitoring hepatobiliary 3.2.1. ALT. ALT (L-alanine:2-oxoglutalate aminoeffects.
transferase, EC 2.6.1.2) is a pyridoxal enzyme which The final category of diagnostic procedures is based catalyzes the reversible interconversion of L-alanine / upon altered liver function. These are methods that a-ketoglutarate to pyruvate / L-glutamate with perimonitor serum albumin, cholesterol, prothrombin time, doxal phosphate as a coenzyme. The presence of low or serum bilirubin as general indicators of the synthetic levels of ALT in the peripheral circulation represents and general metabolic capacity of the liver (Fregia and normal cell turnover or release from nonvascular Jensen, 1994) as opposed to marking some specific toxic sources. Drug-related increases in aminotransferase injury. The serum bilirubin assay will indicate liver activity are typically transitory with values returning injury; however, elevated serum enzyme assays as de-to within normal reference limits within a few weeks scribed above usually reflect hepatotoxicity earlier (Rej, 1989) . (Herlong, 1994) . Although drug-associated hepatic dys-ALT is widely distributed. Human isozymes are function is uncommon in general, severely altered liver found in the cytosol and mitochondria of liver, kidney, function, especially those processes leading to coagula-and skeletal and cardiac muscles (Sakagishi, 1995) . Mition disorders or bilirubin encephalopathy, are indica-tochondrial ALT comprises only a small portion of the tive of severe hepatic injury.
tissue activity and has not been demonstrated in normal human serum. The largest pool of ALT is in the 3.2. Aminotransferases cytosol of hepatic parenchymal cells (Sherman, 1991) . Considerable differences in both the organ distribution Aminotransferases are a group of enzymes that cata-and intracellular compartmentalization of ALT have lyze the reversible transfer of the amino group from been found among species (Hoffmann et al., 1989) . an a-amino acid to an oxo acid. ALT and AST shunt Some nonhuman primates, for example, show little or their amino acid and oxo acid substrates into several no ALT organ specificity (Clampitt and Hunt, 1978) . intermediate pathways. Cytosolic ALT is associated However, overall, serum ALT is one of the most univerwith the utilization of pyruvate in glycolysis, mitochonsal markers for hepatic injury across species. drial ALT is involved in the conversion of alanine to
In the clinical laboratory, the measurement of ALT pyruvate for gluconeogenesis, and AST plays an imis a routine part of serum chemistry panels used to portant role in the transport of reducing equivalents assess hepatic injury. ALT values in healthy blood doacross the mitochondrial membrane (Sakagishi, 1995;  nors, however, can be influenced by age, sex, dietary Rej, 1989) . Hepatocellular damage with the subsechange, geographical location, ethnicity, obesity, longquent disruption of the plasma membrane allows leakterm acetaminophen use, alcohol use, and marital staage of intracellular enzymes such as ALT or AST into tus (Sherman, 1991) , a complicating factor when monithe bloodstream. With some hepatotoxicants, intoring human populations for transaminase elevations creased hepatic synthesis of aminotransferases has following drug exposure. Even the difference in mean also been suggested as a source of increased serum ALT values between males and females in a donor popenzyme levels in hepatocellular injury (Pappas, 1986) . ulation can be significant (Mijovic et al., 1987) . ALT The range of normal is determined by either cutoff activities are elevated for a few days following major values of {2 SD or 97.5 percentile cutoffs in a populaabdominal or thoracic surgery (Stricker et al., 1992a ) tion without known disease. Due to half-lives of apand can also be elevated by the disease being treated. proximately 17 h for AST and 47 h for ALT, the presThe incidence of hepatic damage due to cotrimaoxazole, ence of these enzymes in serum is considered an indicafor example, is around 20% higher in AIDS patients tor of recent hepatocyte injury (Scheig, 1996) . Some (Westphal et al., 1994) compared to other diseases. Cogdrugs actually decrease the activities of serum ALT nizant of these modulating factors in clinical populaand AST. Examples include oxodipine which causes hepatic damage and yet decreases ALT activities in tions, ALT is the single most important indicator of hepatocellular injury for preclinical animal studies, chronic hepatitis, steatosis, metabolic diseases (Fregia et al., 1994) , alcoholic liver disease, and, much less freclinical trials, and postmarketing monitoring.
quently, drug-induced liver disease and nonalcoholic 3.2.2. AST. AST (EC 2.6.1.1) is found in both the steatosis (Renner and Dallenbach, 1992) . In addition, cytosol and mitochondria of hepatocytes (Herlong, some disease states, especially malignancies, produce 1994), but high tissue levels are also found in heart, hepatic effects culminating in elevated transaminases. skeletal muscle, kidney, brain, and pancreas (Rej, 1989) . Accordingly, muscle trauma and surgery by it-
GUIDELINES FOR SERUM TRANSAMINASE
self can lead to AST serum elevations (Clermont and Chalmers, 1967 ). An estimated 60-70% of AST activity in human hepatocytes is localized within mitochondria By international consensus, liver injury, as might be (Schmidt and Schmidt, 1990) . Hence, when found in detected by liver tests, has been defined as an increase blood, AST is considered to be a sensitive indicator of greater than two times the upper limit of normal range mitochondrial damage, especially in the hepatic centri-(ULN) in ALT or conjugated bilirubin or a combined lobular regions which are particularly sensitive to toxic increase in AST, Alk P, and total bilirubin provided and hypoxic liver injury (Schmidt and Schmidt, 1990) . that one of them is greater than two times the ULN It should be noted, however, that depending upon the (Benichou, 1990 ). This injury is further defined as heassay used a number of drugs can reportedly produce patocellular when (1) there is an increase of greater spurious elevations in AST (Davis, 1989) . Serum AST than two times the ULN for ALT alone or (2) there is is affected to a greater degree by alcohol consumption a ratio of serum ALT activity/serum Alk P activity than ALT (Lewis, 1984) . Within these limitations, AST greater than five or cholestatic when there is an inin conjunction with ALT is a very important marker of crease of greater than two times the ULN of Alk P hepatic injury.
ELEVATION AS AN INDICATOR OF LIVER INJURY
alone or a ratio equal or less than two. Acute liver injury is distinguished from chronic liver injury when
NON-DRUG-RELATED TRANSAMINASE ELEVATIONS
the increases have lasted less or more than 3 months, respectively. Severe liver injury and fulminant liver injury are defined by (1) the presence of jaundice, proThe term transaminitis has been applied to mild elethrombin õ50% (or equivalent), and hepatic encephavations of serum aminotransaminases in the absence lopathy and (2) the rapid development of hepatic enof other clinical laboratory abnormalities in asymptomcephalopathy and severe coagulation disorders, respecatic individuals (Hodgson et al., 1989; Rej, 1989) . When tively. observed after drug exposure, these small elevations are often considered as being uninterpretable. A second difficulty in monitoring transaminase levels in patient 6. SERUM ENZYME ELEVATIONS DUE TO HEPATIC populations is the underlying incidence of mildly ab-
ENZYME INDUCTION
normal results in a classical panel of liver tests used in routine monitoring of asymptomatic, unaffected inEnzyme induction is one reported iatrogenic effect leading to elevated hepatic serum enzyme levels in padividuals. These may be associated with population characteristics previously discussed and are not usu-tient populations that are not directly indicative of hepatic injury. This has been well documented, especially ally encountered in preclinical animal toxicology studies. Liver injury tests are abnormal in up to 8% of a for anticonvulsants, but also for some other drugs. In one such study, 56 children of 63 receiving phenobarbihealthy population (Hodgson et al., 1989) . Liver enzyme elevations noted during hospital admission have tal and/or diphenylhydantoin had elevated GGT; 6 had elevated ALT and AST for more than 20 weeks in the been estimated at 5.7-7.6% (Grohmann et al., 1984; Van Dijke et al., 1986) . In one study, 25-30% of asymp-absence of specific histopathology (Aiges et al., 1980) .
Further evidence of hepatic enzyme induction by antitomatic, normal workers had serum chemistries on a five-test liver panel in excess of the established normal convulsants in asymptomatic patients was cited by Wall et al. (1992) in a study of 206 adults and children. range in the absence of risk factors for liver disease (Wright et al., 1988) . Of course, specific estimates of Of these, serum GGT was elevated in 74.6%, Alk P in 29.7%, and ALT in 25.2%. Of 242 patients administered the incidence of abnormal ALT values alone are lower in donor populations. In one study, the frequency of antiepileptic drugs, 40 exhibited high levels of serum GGT and nearly all cases indicated hepatic microsomal elevated ALT in a donor population was reported to be 4.6% above 40 IU/liter in 1986 and appeared to be enzyme induction as measured by antipyrine half-life, leading Hirayanagi et al. (1991) to conclude that, in increasing with time (Mijovic et al., 1987) . In the absence of any intentional drug exposure, extremely high these patients, elevated serum GGT did not necessarily indicate hepatocellular damage. Elevated circulating transaminase levels (ú8-to 10-fold normal) in a patient population may indicate acute viral hepatitis, drug-or levels of GGT are commonly observed in patients taking cytochrome P450 enzyme-inducing drugs such as toxin-mediated liver necrosis, or other damage; persistent mild elevations (2-to 8-fold) are characteristic of rifamicin (Davis, 1989) . Similar studies with co-antiep-ileptic drug therapy (Haidukewych and John, 1986) in-usual susceptibility of an individual. Occurring at therapeutic doses after a variable latent period, these redicated ALT elevations up to three times and AST elevations up to two times the upper limit of normal in sponses are characterized by an incidence of hepatic injury that is very low in frequency within a populamore than one-quarter of the patient population. These were not considered clinically significant but instead tion, dose-independent, and not reproducible in experimental animals (Zimmerman, 1978) . Due to their low were attributed to enzyme induction. Liver biopsies in similar patients undergoing long-term anticonvulsant incidence, idiosyncratic responses are generally not detected until late in the drug development process after therapy showed no signs of chronic liver damage (Jacobsen et al., 1976) . Both ethanol and glucocorticoids a large number of patients have been treated. Although rare, serious adverse liver responses may include fulhave been shown to induce GGT activity in rat liver (Nishimura et al., 1981; Billon et al., 1980) . In studies minant hepatitis and cholestasis. These account for many drug-induced deaths worldwide. Drugs withwith both man and rat, the primary cause for increased GGT associated with prolonged alcohol exposure has drawn from the market due to idiosyncratic drug reactions, including or due solely to hepatotoxicity, include been attributed to hepatic enzyme induction rather than liver cell injury (Teschke et al., 1983) , although benoxaprofen, ibufenac, temafloxacin, tenilic acid , nomifensine, and perhexilene (Breckenit is clear that ethanol is hepatotoxic in general. In developing rats, cortisol enhances hepatic activities of ridge, 1996).
Etiologically, these reactions are of two major types: ALT (Herzfeld and Raper, 1979) .
(1) aberrant metabolism-based responses leading to the accumulation of toxic metabolites in susceptible indi-
TYPES OF DRUG HEPATOTOXICTY
viduals and (2) hypersensitivity or immune-based tox-7.1. Intrinsic Hepatotoxicity icity. Other mechanisms may include abnormal receptor sensitivity, latent biochemical abnormalities, or One of two major categories of chemicals that can multifactorial causes . Almost all hepproduce dose-dependent, hepatic injury, either directly atotoxic reactions to antibacterials (George and Crawor indirectly via a metabolite, includes the intrinsic or ford, 1996) or NSAIDs (Boelsterli et al., 1995) , espe-''direct'' (type A) hepatotoxicants. These responses of-cially of the indole, pyrazole, and propionic acid classes ten can be anticipated from the known pharmacology (Lewis, 1984) , are idiosyncratic. Mechanisms may be of the drug, are generally detectable in animal models, primarily metabolite-dependent (isoniazid, diclofenac), and occur more frequently or with greater severity hypersensitivity-mediated (beta-lactams, sulindac), or when exposure is increased, i.e., with increasing dose both (sulfonamides, erythromycin derivatives) (Westlevels or duration of dosing. Salicylates (Lewis, 1984 (Lewis, ) phal et al., 1994 Miyamoto et al., 1997; Boelsterli et and acetaminophen (Fry and Seeff, 1995) are examples al., 1995). Some notable histamine (H 2 )-receptor antagof analgesics that produce intrinsic liver toxicity. At onists and a number of antidepressants are associated high blood levels, aspirin can produce hepatocellular with hepatic idiosyncratic reactions, presumably mediinjury, confirmed by liver biopsy studies (focal necro-ated via chemically reactive metabolites (Black, 1987; sis) , with 10-to 40-fold elevations for serum transami-Pirmohamed et al., 1992) . nases noted (Zimmerman, 1978) . Chemotherapeutic agents often possess predictable, dose-dependent hepa-7.2.1. Metabolism-based toxicity. Interindividual totoxicity (King and Perry, 1995) , even though they do variations of drug effects are most frequently explained not intentionally target slowly dividing hepatocytes. by genetic variation or polymorphism of drug metaboTetracycline, methotrexate, mercaptopurine (Finlay-lism. Based on immunogenicity and catalytic activities, son, 1973), and possibly suldinac (Boelsterli et al., approximately 20 human cytochrome P450 isozymes 1995) are other examples of direct hepatotoxins. Intrin-have been identified (Larrey and Pageaux, 1997) comsic hepatotoxins produce injury in a large percentage prising at least 10 distinct P450 gene families (Watof exposed individuals after a short fixed latent period kins, 1990). Of these, cytochromes CYP1A2, CYP2C9, either by direct, nonselective physicochemical distor-CYP2C19, CYP2E1, and, in particular, CYP2D6 and tion or disruption of hepatocytes or by indirect interfer-CYP3A are especially important for the hepatic metabence with specific metabolic processes leading to struc-olism of drugs (Brockmoller and Roots, 1994) . While tural damage (Lewis, 1984) . This type of toxicity can bioactivation of a drug to a toxic metabolite may reprebe alleviated by dose reduction in patient populations. sent õ1% of the overall metabolism of that drug (Pirmohamed et al., 1996) , specific reactive metabolites 7.2. Idiosyncratic Hepatotoxicity may directly lead to hepatic injury or may act via the immune system. Genetic deficiencies in hepatic cytoAlthough a number of drugs, as for example some chrome CYP2D6, CYP2C19, N-acetyltransferase 2 antineoplastic agents (McDonald and Tirumali, 1984) , (NAT2), and glutathione synthetase have been cited exhibit intrinsic toxicity in man or animals, most hepato explain individual variations in drug hepatotoxicity totoxic drug reactions in humans are considered to be idiosyncratic (King and Perry, 1995) , i.e., due to un-(Larrey and Pageaux, 1997; Meyer, 1996) . Seven muta-tions of the NAT2 gene are known to define numerous a generalized type of idiosyncratic drug reaction mediated through the immune system may also involve the alleles associated with decreased function, and two mutant alleles of CYP2C19 have been described in poor liver (Uetrecht, 1988) . metabolizers (Meyer and Zanger, 1997; Goldstein and de Morias, 1994 (Meyer and Zanger, 1997) els at high doses. Thus, the same drug can be an intrinleading to a wide range of interindividual variability sic hepatotoxicant in one or more animal models and in CYP2D6-based response in a healthy population yet cause an idiosyncratic liver response in some hu- (Spina et al., 1994) . For example, patients receiving the mans. Some of the angiotensin-converting enzyme inantianginal agent perhexiline maleate who are defihibitors used for the treatment of hypertension and cient in CYP2D6 can develop hepatotoxicity due to percongestive heart disease fall into this category. Captohexiline accumulation (Morgan et al., 1984) . Although pril, for example, has been associated with the rare it is not subject to genetic polymorphism (Ereshefsky, incidence of hepatotoxicity in humans (Rahmat et al., 1996) , both genetic and nongenetic factors lead to 1985; Tabibian et al., 1987) . In mice, acute high doses marked (5-to 20-fold) individual variability in metaof captopril cause moderate increases in ALT, debolic clearance via CYP3A (Wilkinson, 1996) which creases in hepatic GSH, and histological evidence of comprises 25% of the total hepatic cytochrome system. hepatic necrosis with 24 h (Helliwell et al., 1985) . EnaThis leads to wide variations in individual exposure lapril maleate which has been reported to cause a rare levels to drugs such as cyclosporine (Watkins, 1990) .
but potentially serious hepatotoxicity in humans, was Polymorphism has also been described for CYP2C9 and demonstrated by Jurima-Romet and Huang (1992) to CYP2E1 (Meyer and Zanger, 1997) . The latter is improduce centrilobular necrosis and significant moderportant for the metabolism of general anesthetics such ate increases in ALT and AST 24 h after acute exposure as halothane which causes hepatitis in 1 in 35,000 pain Fisher 344 rats. tients on first exposure and in 1 in 3700 patients upon multiple exposures (Pirmohamed et al., 1996) .
THERAPEUTIC CLASS AND DRUG-INDUCED HEPATIC INJURY
Immune system-based toxicity.
Immunebased injuries represent the other major mechanism for idiosyncratic responses in humans. Autoimmunity
The frequencies of drug-induced hepatitis at theratriggered by xenobiotics involves the modification of peutic doses vary among drug classes with some classes host tissues or immune cells by the chemical so that more consistently demonstrating low levels of hepatic self-antigens are erroneously targeted; drug hypersen-injury than others. These can vary from 1/100 for a few sitivity or allergy refers to a situation where the im-compounds, to 1/10,000 for some intermediate commune system responds in an exaggerated or inappro-pounds, to 1/100,000 for others (Larrey and Pageaux, priate manner (Burns et al., 1996) by one of four mecha-1997). For one antitumor antibiotic, elevations of aminisms (Combs and Gell, 1975) . Most autoimmune notransferases can occur in up to 100% of patients diseases are associated with specific alleles of the major (King and Perry, 1995) . In one large study (Sameshima histocompatibility complex (MHC) class II genes (Fro-et al., 1984) based on 8156 case histories of drug-innek et al., 1991). The high level of polymorphism that duced hepatic injury over a 70-year period in Japan, is characteristic of the MHC genes may lead to subpop-the greatest number of cases was due to antibiotics ulations of individuals who are highly immune to re-(34%), followed by CNS drugs (15%), chemotherapeutic sponses toward drug-related antigens (Park et al., drugs (14%) , cardiovascular drugs (11%), carcinostatic 1992). Four major categories of drugs known to cause drugs (7%), hormones and hormone antagonists (6%), autoimmune responses include hydrazines, derivatives diagnostic aids (4%), and other drugs (9%). A smaller of aromatic amines, sulfhydryl-containing compounds, study based on 46 patients representing 20% of paand compounds with a phenol ring (Adams and Hess, tients admitted for acute or chronic hepatitis during 1991). Specific examples of drugs known or suspected a 3-year period cited anti-inflammatories, antibiotics, of causing hepatitis via an autoimmune mechanism antihypertensives, and diuretic drugs as being most include methyldopa, oxypehnisatin, isoniazid, nitrofu-frequently implicated (Grippon et al., 1985) . In the U.S. rantoin, clometacin, fenofibrate, papaverine, and tie-Physicians Desk Reference, transaminase elevations, nilic acid (Bigazzi, 1988) . Although other nongenetic albeit usually minor and infrequent, are not uncommon factors may be involved in the etiology of altered im-for drugs classified as antineoplastic compounds, neumune responses, the role of drug metabolism polymor-rotrophic drugs, and antibiotics/antibacterials. Table 1 phism leading to bioactivation is an important one. Ex-summarizes available information for some of these drug categories. trahepatic metabolism of some drugs associated with 
DRUGS FREQUENTLY ASSOCIATED
man populations are affected by a variety of both genetic and environmental factors. In addition, some se-WITH HEPATOTOXICITY rum enzymes of hepatic origin used for assessment of Some marketed drugs have been associated with a liver injury or disease can be increased by hepatic enhigh, predictable incidence of suspected hepatotoxicity zyme induction instead of or in addition to membrane in human populations, as, for example, they may cause leakage caused by hepatic damage. Within these limiasymptomatic, transient elevations in serum transami-tations, guidelines for the detection of hepatic injury nase levels in ¢10% of the patient population. It should via these biochemical markers have been established. be noted that the actual frequency of isolated, asymp-
The hepatic metabolism of drugs to reactive toxicants tomatic elevations of transaminases in patient popula-or protein-binding moieties is the single most imtions may actually be understated because liver func-portant, but by no means the only mechanism leading tion tests are not routinely ordered during routine clini-to hepatic injury. Unlike preclinical laboratory animals cal practice (Jick, 1995) . Some examples are shown in which are relatively homogenous in terms of their con- Table 2 . Likewise, drug interaction, disease complica-stitutive hepatic cytochrome P450 isozymes, human tions, viral infections, or combinations of drugs may be populations are remarkably diverse with cytochrome responsible, in part, for some of these effects.
P450 enzyme polymorphisms and other individual differences in drug-metabolizing enzyme systems being prevalent. Subtle individual differences in the hepatic
DISCUSSION
detoxification processes or the formation of minor but Drug-induced liver toxicity can be detected at various highly reactive metabolites in susceptible individuals stages of drug development depending upon the mecha-can lead to rare but unpredictable consequences as an nism responsible for hepatic injury. Intrinsic hepato-increasing proportion of the population is exposed to a toxicants are effectively identified in the preclinical drug at therapeutic doses. Frequently, these idiosyntesting stage using animal models at doses much cratic responses are caused by an aberrant immune higher than the intended human dose while, at the response to the drug or a drug-altered self-antigen. For other extreme, rare but sometimes fatal idiosyncratic both direct, intrinsic toxic responses in humans or laboresponses can only be discovered after the exposure of ratory animals and isolated idiosyncratic responses in thousands of patients to therapeutic levels of the drug. a clinical setting, early evidence of hepatic injury is Elevated serum transaminases, especially ALT, are the obtained via biochemical methods including the monisingle most important laboratory indicators of hepatic toring of serum transaminases. effects from early preclinical testing to the postmarket While knowledge of the typical human metabolism monitoring of patients responding to a variety of histo-of experimental drugs will not predict idiosyncratic hepatic toxicity, it can be useful in determining similarilogic effects. Baseline serum transaminase levels in hu- AST, and (1980) , Pessayre (1992), LDH reported. Porubek et al. (1984) , PDR ties between species that may lead to intrinsic toxicity established with specific liver injury, these techniques may be useful in detecting hepatotoxic potential preor to explain tolerance or sensitivity to the hepatic toxicity of a compound in one species versus another. Cur-clinically, even at therapeutic doses.
Idiosyncratic responses remain difficult to assess at rent in vitro laboratory procedures utilize isolated microsomal preparations or specific recombinant human a preclinical or early clinical level. Using separate cultures from several donors, it may be possible to expose cytochrome products in conjunction with chromatographic procedures for the detection and identification human hepatocytes to higher concentrations of a drug than would be found in clinical practice in order to of drug metabolites. In vitro methods have been used to predict the in vivo drug metabolism of verapamil, forcibly detect idiosyncratic responses due to minor reactive metabolites that do not involve the immune sysloxidine, diazepam, lidocaine, phenacetin, and some other compounds in the human liver (Iwatsubo et al., tem. Because most compounds that have been tested do cause observable changes in liver gene expression 1997). In a similar manner, in vitro comparisons of drug toxicity in metabolizing rat, dog, monkey, and, (Anderson et al., 1996) and idiosyncratic hepatotoxins such as diclofenac, halothane, tienilic acid, and valproic where possible, human hepatocyte cultures can be used for the preclinical assessment of drug hepatic toxicity among others are known to form protein adducts (Pumford and Halmes, 1997), protein analysis by two-dimenusing the same clinical chemistry end points, namely the transaminases, that are used in vivo. Primary he-sional gel electrophoresis may provide a useful preclinical screening too. Future developments in assays may patocytes cultured on an extracellular collagen matrix in time form bile canaliculi (LeCluyse et al., 1994) pro-include determinations of drug effects on transgenic animals expressing human MHC class I and II and viding the opportunity to study the effects of drugs on the hepatobiliary system in vitro. Examples of the associated genes (Campbell and Milner, 1993) , utilization of the sensitive reporter antigen/popliteal lymph successful use of hepatocyte cultures from humans and other species to study hepatic effects include the me-node assay (Albers et al., 1997) , the comparative testing of a compound at high doses or concentrations in tabolism of adinazolam, the cytotoxicity of trospectomycin, and the human-specific hepatotoxicity of panad-transgenic animals or cell lines expressing various constitutive human cytochrome P450s, or the testing of iplon (Ulrich et al., 1995) .
Recent developments that may have application in preclinical candidates in rodent strains genetically diverse in terms of the hepatic cytochrome P-450 system. preclinical testing for potential liver toxicity include procedures that have evolved in conjunction with combinatorial chemistry and pharmacological screening 11. CONCLUSIONS methods (see Lam, 1997) . Screening methods of particular interest include genomic and proteonomic assays
• The incidence of drug-induced hepatic injury varies among the different drug classes as well as within that are sensitive and plenary by nature, although they may be of limited value in revealing specific toxicities. a drug class. Intrinsic responses are generally detected early in the discovery and development process, while These methods depend heavily upon automation, the availability of specific probes or libraries for pattern host-dependent, idiosyncratic responses are usually not detectable during the early phases of development recognition, and advanced computer systems. The ultimate advantage of these techniques would be the detec-due to their rarity.
• Of the various clinical laboratory markers for hetion of early cellular events, as, for example, markers of oxidative damage, at therapeutic dose levels that patic injury, serum transaminases, especially ALT, are the most universally important indicators for studies may predispose the organism to frank toxicity with sustained exposure. Examples of gene expression in liver ranging from early preclinical animal testing to postmarketing patient monitoring. Serum ALT is elevated after toxic injury include heat shock and oxidative stress-inducible genes (Schiaffonati and Tiberio, 1997) . in response to several categories of hepatic lesions in multiple species. However, slight transaminase elevaBoth induction and suppression of gene expression can occur with some gene families (Runge-Morris, 1997). tions following drug exposure in humans must be interpreted with care due to the many extrinsic factors Reactive intermediates of xenobiotics often bind covalently to proteins as conjugates or adducts leading to known to elevate transaminases.
• The hepatic metabolism of drugs to reactive toxieither direct toxicity or immune-mediated toxicity (Pumford et al., 1997) . In addition to the modification cants or protein-binding moieties is a frequently encountered mechanism leading to hepatic injury. Subtle of cellular proteins, xenobiotics may modify protein expression (Richardson et al., 1994) . Two-dimensional gel individual differences in the hepatic detoxification processes or the formation of minor but highly reactive electrophoresis techniques have been described that allow the resolution and quantitation of hundreds of metabolites in susceptible individuals can lead to rare but unpredictable consequences as an increasing proliver proteins that may be altered by the toxic effects of xenobiotics (Anderson et al., 1996) . If a clear associa-portion of the population is exposed to a drug at therapeutic doses. Improvements in the metabolic profiling tion between either altered gene expression or specific changes in protein structure and abundance can be of drugs using in vitro microsomal systems expressing Coombs, R. R. A., and Gell, P. G. H. (1975) . Classification of allergic multiple human cytochromes during the preclinical reactions responsible for clinical hypersensitivity and disease. In testing phase may enhance our ability to anticipate Clinical Aspects of Immunology (P. G. H. Gell, R. R. A. Coombs, both intrinsic and idiosyncratic toxic responses. will continue to be an important clinical laboratory pro- Craxi, A., and Almasio, P. (1996) . Diagnostic approach to liver enzyme elevation. J. Hepatol. 25(Suppl. 1), 47-51. cedure for the assessment of preclinical hepatotoxicity, Dansette, P. M., Amar, C., Valadon, P., Pons, C., Beaune, P. H., and new developments involving comparative toxicity Mansuy, D. (1991 
